证券代码：600587 证券简称：新华医疗 公告编号：临 2026-013 山东新华医疗器械股份有限公司 关于子公司产品获得二类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）子公司 山东新华医用环保设备有限公司于近日收到山东省药品监督管理局颁发的《中华人 民共和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证的具体情况 1、产品名称：医用中心吸引系统 2、注册证编号：鲁械注准 20262140119 3、注册人名称：山东新华医用环保设备有限公司 4、注册人住所：山东省淄博高新区新华医疗科技园 5、生产地址：山东省淄博高新区万杰路 88 号 6、结构及组成：医用中心吸引系统主要由中心吸引站、管道、阀门及其终端 等组成。 7、型号、规格：XH-X 8、适用范围：用于医院向手术室、抢救室、治疗室和病房终端提供负压，产 生吸力。 9、批准日期：2026 年 03 月 23 日 10、有效期至：2031 年 03 月 22 日 11、同类产 ...

关于子公司产品获得三类医疗器械注册证的公告 证券代码：600587 证券简称：新华医疗 公告编号：临 2026-012 山东新华医疗器械股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）子公司 新华手术器械有限公司于近日收到国家药品监督管理局颁发的《中华人民共和国医 疗器械注册证》，具体情况如下： 一、医疗器械注册证的具体情况 1、产品名称：一次性使用腹腔内窥镜高频手术器械 2、注册证编号：国械注准 20263010413 3、注册人名称：新华手术器械有限公司 4、注册人住所：山东省淄博市高新区齐祥路 2779 号 5、生产地址：山东省淄博市高新区尊贤路 2999 号新华健康产业园 A2（委托 生产） 6、结构及组成：产品由单极抓钳、单极分离钳、单极剪刀、单极电极、双极 电凝钳组成。 7、型号、规格：单极抓钳 HDJZQ103、单极抓钳 HDJZQ105、单极抓钳 HDJZQ305、 单极抓钳 HDJZQ205、单极分离钳 HDJFL105、单极分 ...

Core Viewpoint - The blood dialysis machine market in China is experiencing rapid growth, with the market size expected to reach 4.131 billion yuan by 2025, reflecting a year-on-year increase of 6.4% [1][6]. Industry Overview - Blood dialysis machines, also known as artificial kidneys, are essential medical devices for treating renal failure and uremia, consisting of a blood monitoring alarm system and a dialysis liquid supply system [3][4]. - The increasing elderly population and rising prevalence of chronic kidney diseases are driving the demand for blood dialysis machines [5][6]. Market Size and Growth - The market size for blood dialysis machines in China is projected to grow significantly, driven by an aging population and an increasing number of patients requiring dialysis treatment [1][6]. - The number of patients undergoing dialysis in China is expected to rise from 385,100 in 2015 to 1,027,300 by 2024, with male patients making up a significant portion of this demographic [5][6]. Competitive Landscape - The Chinese blood dialysis machine industry is primarily dominated by foreign companies such as Fresenius Medical, B. Braun, Baxter, and Nipro, indicating substantial room for domestic companies to capture market share [7][8]. - Domestic companies are enhancing their R&D capabilities, leading to improvements in technology and product quality, which positions them to compete more effectively against international brands [7][8]. Industry Development Trends - The process of domestic substitution for blood dialysis machines is accelerating, with local companies focusing on core technology and key component development to reduce reliance on foreign brands [10][11]. - Future technological advancements in blood dialysis machines will focus on smart and precise upgrades, integrating IoT and AI for improved monitoring and safety [11][12]. - The application scenarios for blood dialysis machines are expanding beyond traditional hospitals to include community healthcare settings and home dialysis solutions, driven by the increasing demand for accessible and convenient treatment options [12].

Group 1 - The company held its first extraordinary general meeting of shareholders on February 25, 2026, at the Xinhua Medical Technology Park in Zibo City [1] - The meeting was chaired by the chairman Wang Yuquan and utilized a combination of on-site and online voting, complying with the Company Law and the company's articles of association [1] - All 11 current directors attended the meeting, along with key executives including the general manager and financial director [1] Group 2 - The law firm Beijing Junzhi Law Firm, represented by lawyers Wang Haiqing and Li Chenk, provided legal verification for the meeting [2] - The legal opinion concluded that the procedures for convening and holding the meeting were in accordance with the Company Law and the company's articles of association, and the resolutions passed were valid [2]

Core Viewpoint - Xinhua Medical emphasizes its commitment to regulatory compliance and transparent information disclosure, stating that its stock price fluctuations are influenced by multiple market factors, while the company will focus on its core business development to protect shareholder interests [1] Group 1 - The company adheres strictly to regulatory requirements for information disclosure [1] - The operational status of the company is accurately reflected in its periodic reports [1] - Stock price volatility is attributed to various market factors [1] Group 2 - The company is committed to focusing on its main business development [1] - The company aims to effectively safeguard the interests of all shareholders [1]

Core Viewpoint - The company has terminated its equity acquisition without any payment or breach of contract, and this decision has not adversely affected its financial status or normal operations [1] Group 1: Company Actions - The company will continue to strictly adhere to regulatory requirements and make prudent external investment decisions [1] - The company aims to enhance the transparency of its information disclosure [1] - The company is committed to deepening its focus on the medical device sector to solidify its intrinsic value through stable operational performance [1] Group 2: Investor Relations - The company emphasizes the importance of strengthening communication with investors [1] - The company is dedicated to safeguarding the legitimate rights and interests of all shareholders [1]

证券代码：600587 证券简称：新华医疗 公告编号：临 2026-011 山东新华医疗器械股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 与网络投票相结合的方式表决，符合《公司法》、《公司章程》等法律、法规及规 范性文件的规定。 (五) 公司董事和董事会秘书的列席情况 1、公司在任董事11人，列席11人； 2、 公司总经理巩报贤先生、副总经理兼董事会秘书李财祥先生、副总经理屈靖 先生、董事兼财务总监周娟娟女士、副总经理朱庆国先生、副总经理王加强 先生出席了会议。 二、 议案审议情况 | 议案 | 议案 | 得票数 | 得票数占出席会议有效 | | 是否当选 | | --- | --- | --- | --- | --- | --- | | 序号 | 名称 | | 表决权的比例（%） | | | | 1.01 | 赵军 | 184,003,247 | | 99.0130 | 是 | (二) 涉及重大事项，5%以下股东的表决情况 一、 ...

北 京 市 东 城 区 北 三 环 东 路 36 号环球 贸易中心 B 座 11 层 电话（Tel）： 52213236/7 邮编（P.C）： 100013 北京市君致律师事务所 关于山东新华医疗器械股份有限公司 2026 年第一次临时股东会的法律意见书 致：山东新华医疗器械股份有限公司 北京市君致律师事务所（以下简称"本所"）受山东新华医疗器械股份有限公 司（以下简称"公司"）的委托，指派律师出席 2026 年 2 月 25 日上午 9:00 点召 开的公司 2026 年第一次临时股东会（以下简称"本次股东会"）；依据《中华人民 共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称 "《证券法》"）、《上市公司股东会规则》（以下简称"《股东会规则》"）等现行 法律、法规和其他规范性文件及《山东新华医疗器械股份有限公司章程》的规定， 特就公司本次股东会相关事宜，出具本法律意见书。 对本法律意见书的出具，本所特作如下声明： 一、本次股东会召集、召开的程序 公司董事会于 2026 年 1 月 30 日作出决议召集本次股东会，并于 2026 年 1 月 31 日在《中国证券报》、《上海证券报 ...

Core Viewpoint - On February 23, a total of 34 listed companies had their restricted shares unlocked, with a total market value of approximately 19.007 billion yuan [1] Group 1: Restricted Share Unlocking Details - Luzhou Laojiao (000568) had 2.0425 million shares unlocked under equity incentive restrictions - AVIC Xi'an Aircraft Industry (000768) had 4.3606 million shares unlocked under equity incentive restrictions - Hubei Energy (000883) had 19.2779 million shares unlocked under equity incentive restrictions - Jining Pharmaceutical (000919) had 1.92 million shares unlocked under equity incentive restrictions - Guangji Pharmaceutical (000952) had 2.5209 million shares unlocked under equity incentive restrictions - China Software (600536) had 57,200 shares unlocked under equity incentive restrictions - Xinhua Medical (600587) had 1.7845 million shares unlocked under equity incentive restrictions - Baoxin Software (600845) had 10.2578 million shares unlocked under equity incentive restrictions - China Railway (601390) had 55.9338 million shares unlocked under equity incentive restrictions - China Communications Construction (601800) had 5.593 million shares unlocked under equity incentive restrictions - StarNet Ruijie (002396) had 2.8342 million shares unlocked under equity incentive restrictions - Lopuskin (002333) had 22.3212 million shares unlocked under A-share issuance to legal persons - Wanbangda (300055) had 33.6538 million shares unlocked under A-share issuance to legal persons - Hangyang Co., Ltd. (002430) had 5.2049 million shares unlocked under equity incentive restrictions - Taijia Co., Ltd. (002843) had 949,600 shares unlocked under equity incentive restrictions - Nanda Optoelectronics (300346) had 130,000 shares unlocked under equity incentive restrictions - Anhui Natural Gas (603689) had 2.5064 million shares unlocked under equity incentive restrictions - Zhongyan Dadi (003001) had 97,200 shares unlocked under equity incentive restrictions - Yuanxiang New Materials (301300) had 30.2983 million shares unlocked with extended lock-up period - Yidao Information (001314) had 88.6187 million shares unlocked under pre-issuance restrictions - Tongda Electric (603390) had 579,500 shares unlocked under equity incentive restrictions - Yangzhou Jinqiao (603307) had 50 million shares unlocked under pre-issuance restrictions - Aili Home (603221) had 2.29 million shares unlocked under equity incentive restrictions - Zhili Fang (301312) had 333,900 shares unlocked under equity incentive restrictions - Kuntai Co., Ltd. (001260) had 83.25 million shares unlocked under pre-issuance restrictions - Entropy Technology (301330) had 92.5223 million shares unlocked with extended lock-up period - Yatong Precision (603190) had 596,100 shares unlocked under pre-issuance restrictions - Sanwang Communication (688618) had 87,400 shares unlocked - Longxun Co., Ltd. (688486) had 30.6312 million shares unlocked - Dize Pharmaceutical (688192) had 991,100 shares unlocked - Haohan Depth (688292) had 57.5177 million shares unlocked - Haizheng Biomaterials (688203) had 78.5601 million shares unlocked - Diaomicro (688381) had 55.9536 million shares unlocked - Zhongrun Optics (688307) had 29.8507 million shares unlocked [1]

Core Viewpoint - The announcement details the unlocking and listing of restricted stocks under the 2021 stock incentive plan of Shandong Xinhua Medical Instrument Co., Ltd, with 2,282,513 shares set to be released on February 24, 2026 [2][4][18]. Group 1: Stock Incentive Plan Overview - The stock type being listed is part of the stock incentive plan, with a total of 2,282,513 shares to be unlocked [2][3]. - The third phase of the restricted stock under the 2021 incentive plan is being unlocked, with the unlocking date set for February 24, 2026 [4][16]. Group 2: Approval and Implementation Process - The stock incentive plan was approved during the board meeting on November 24, 2021, with independent directors providing their opinions [5][6]. - The plan underwent necessary public disclosures and received approvals from relevant authorities, including the State-owned Assets Management Unit [8][9]. Group 3: Unlocking Conditions and Details - The unlocking conditions for the third phase have been met, as confirmed by the board, allowing 324 eligible participants to unlock a total of 2,282,513 shares, which represents approximately 0.38% of the company's total share capital [17][20]. - The specific conditions for unlocking include performance metrics that align with the company's strategic goals [16]. Group 4: Stock Listing and Transfer Restrictions - The shares will be listed for trading on February 24, 2026, with specific transfer restrictions for directors and senior management during their tenure and for six months post-departure [18][19]. - The company will retain rights to any profits made from shares sold within six months of purchase or sale by directors and senior management [18]. Group 5: Independent Opinions and Legal Compliance - Independent directors have expressed that the unlocking process complies with relevant regulations and does not harm the interests of the company or its shareholders [20]. - Legal opinions confirm that all necessary approvals and procedures have been followed for the unlocking of shares [21].